M87 M87.1
Conditions
Interventions
Group 1: This non-interventional study will be conducted at hematological practices, oncological urologists and gynecologists and oncological outpatient wards of appropriate clinics based on a total s
Sponsors
AxioNovo Gmbh
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - 18 Years old - Informed consent was singed correctly - Patient has advanced tumor disease which extended to the skeletal or elevated calcium serum levels as a result of malignant tumor growth -Therapeutic decision was made independently from a possible NIS enrollment - Patient does not participate in a clinical trial
Exclusion criteria
Exclusion criteria: - Contraindications to the use of zoledronic acid according to the SmPC. - The current therapy was started more than 12 weeks ago. - The patient is participating in a clinical trial at the same time. - Pregnancy is present or the patient is breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy and Tolerability routine practice. Observational, non-interventional study. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects which were not observed so far. | — |
Countries
Germany
Contacts
Public ContactBurkard Heckelbacher
Datafaber GbR
Outcome results
None listed